OPTIMOX3_3A | R Documentation |
Kaplan-Meier digitized data from OPTIMOX3, figure 3A (PMID 26474518). A reported sample size of 700 for a primary endpoint of PFS in colorectal cancer.
OPTIMOX3_3A
A data frame of 452 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (bev, bev_erlotinib) | |
Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1493–505.
summary(OPTIMOX3_3A)
kmplot(OPTIMOX3_3A)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.